Skip to content

Study · Not a test of the peptide alone · 2023

6 results

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension.

Ramchand SK, David NL, Lee H, Bruce M, Bouxsein ML, Tsai JN, Leder BZ

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research23 Nov 2022Cited by 8 (Europe PMC)

PMID36333954 (opens in a new tab)PMCIDPMC10098948 (opens in a new tab)DOI10.1002/jbmr.4737 (opens in a new tab)PepBankPUB-36333954
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In postmenopausal women, total BMD declined after zoledronic acid following teriparatide and denosumab, reaching baseline at radius but remaining elevated at tibia.

    In plain wordsIn postmenopausal women, total BMD declined during sequential therapy, reaching baseline at radius but remaining above baseline at tibia.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTotal peripheral BMD
    Study

    n = 53

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Despite ZOL administration, total and cortical BMD gradually decreased over 27 months resulting in values similar to baseline at the radius but still significantly above baseline at the tibia.
    3 context sentences
    Summary · context
    In the 15-month DATA-HD study, 76 postmenopausal osteoporotic women were randomized to receive 9 months of teriparatide (20-μg or 40-μg daily) overlapped with denosumab (60 mg at months 3 and 9).
    Summary · context
    In the Extension study, 53 participants received a single dose of ZOL (5 mg intravenously) 24-35 weeks after the last denosumab dose.
    Summary · context
    We measured volumetric BMD and microarchitecture at the distal radius and tibia using high-resolution peripheral quantitative computed tomography at months 27 and 42.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In postmenopausal women, cortical BMD declined after zoledronic acid following teriparatide and denosumab, reaching baseline at radius but remaining elevated at tibia.

    In plain wordsIn postmenopausal women, cortical BMD declined during sequential therapy, reaching baseline at radius but remaining above baseline at tibia.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCortical peripheral BMD
    Study

    n = 53

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Despite ZOL administration, total and cortical BMD gradually decreased over 27 months resulting in values similar to baseline at the radius but still significantly above baseline at the tibia.
    3 context sentences
    Summary · context
    In the 15-month DATA-HD study, 76 postmenopausal osteoporotic women were randomized to receive 9 months of teriparatide (20-μg or 40-μg daily) overlapped with denosumab (60 mg at months 3 and 9).
    Summary · context
    In the Extension study, 53 participants received a single dose of ZOL (5 mg intravenously) 24-35 weeks after the last denosumab dose.
    Summary · context
    We measured volumetric BMD and microarchitecture at the distal radius and tibia using high-resolution peripheral quantitative computed tomography at months 27 and 42.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 03HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In postmenopausal women receiving sequential therapy, cortical porosity at both sites fell below baseline at month 27, then rose through month 42.

    In plain wordsIn postmenopausal women receiving sequential therapy, cortical porosity fell below baseline at both sites, then rose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedCortical porosity
    Study

    n = 53

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    At both sites, cortical porosity decreased to values below pretreatment baseline at month 27 but then increased from month 27 to 42.
    3 context sentences
    Summary · context
    In the 15-month DATA-HD study, 76 postmenopausal osteoporotic women were randomized to receive 9 months of teriparatide (20-μg or 40-μg daily) overlapped with denosumab (60 mg at months 3 and 9).
    Summary · context
    In the Extension study, 53 participants received a single dose of ZOL (5 mg intravenously) 24-35 weeks after the last denosumab dose.
    Summary · context
    We measured volumetric BMD and microarchitecture at the distal radius and tibia using high-resolution peripheral quantitative computed tomography at months 27 and 42.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 04HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In postmenopausal women, trabecular parameters did not significantly change during post-zoledronic-acid follow-up after teriparatide and denosumab.

    In plain wordsIn postmenopausal women receiving sequential therapy, trabecular parameters did not significantly change during follow-up after zoledronic acid.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTrabecular parameters
    Study

    n = 53

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    There were no significant changes in trabecular parameters throughout the 27-month post-ZOL observation period.
    3 context sentences
    Summary · context
    In the 15-month DATA-HD study, 76 postmenopausal osteoporotic women were randomized to receive 9 months of teriparatide (20-μg or 40-μg daily) overlapped with denosumab (60 mg at months 3 and 9).
    Summary · context
    In the Extension study, 53 participants received a single dose of ZOL (5 mg intravenously) 24-35 weeks after the last denosumab dose.
    Summary · context
    We measured volumetric BMD and microarchitecture at the distal radius and tibia using high-resolution peripheral quantitative computed tomography at months 27 and 42.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 05HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In postmenopausal women receiving sequential therapy, stiffness declined at radius and tibia but remained above baseline at tibia.

    In plain wordsIn postmenopausal women receiving sequential therapy, bone stiffness declined at both sites but remained above baseline at tibia.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePeripheral bone stiffness
    Study

    n = 53

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Stiffness and failure load, at both sites, decreased progressively from month 15 42 though remained above baseline at the tibia.
    3 context sentences
    Summary · context
    In the 15-month DATA-HD study, 76 postmenopausal osteoporotic women were randomized to receive 9 months of teriparatide (20-μg or 40-μg daily) overlapped with denosumab (60 mg at months 3 and 9).
    Summary · context
    In the Extension study, 53 participants received a single dose of ZOL (5 mg intravenously) 24-35 weeks after the last denosumab dose.
    Summary · context
    We measured volumetric BMD and microarchitecture at the distal radius and tibia using high-resolution peripheral quantitative computed tomography at months 27 and 42.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 06HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In postmenopausal women receiving sequential therapy, failure load declined at radius and tibia but remained above baseline at tibia.

    In plain wordsIn postmenopausal women receiving sequential therapy, failure load declined at both sites but remained above baseline at tibia.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePeripheral bone failure load
    Study

    n = 53

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Stiffness and failure load, at both sites, decreased progressively from month 15 42 though remained above baseline at the tibia.
    3 context sentences
    Summary · context
    In the 15-month DATA-HD study, 76 postmenopausal osteoporotic women were randomized to receive 9 months of teriparatide (20-μg or 40-μg daily) overlapped with denosumab (60 mg at months 3 and 9).
    Summary · context
    In the Extension study, 53 participants received a single dose of ZOL (5 mg intravenously) 24-35 weeks after the last denosumab dose.
    Summary · context
    We measured volumetric BMD and microarchitecture at the distal radius and tibia using high-resolution peripheral quantitative computed tomography at months 27 and 42.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.